Low-grade non-Hodgkin's lymphoma - Biology and therapeutic approaches

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 2, 1997, Pages 150-155

  Bentley, M ^a   Taylor, K ^a  

^a MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; FLUDARABINE; GAMMA INTERFERON; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; INTERLEUKIN 4; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MITOXANTRONE; PREDNISONE; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUSTRALIA; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHROMOSOME ABERRATION; COMPUTER ASSISTED TOMOGRAPHY; FOLLICULAR LYMPHOMA; HUMAN; LYMPH NODE BIOPSY; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHODGKIN LYMPHOMA; ONCOGENE; PROGNOSIS; REVIEW; TUMOR CLASSIFICATION;

EID: 0030920733     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb00930.x     Document Type: Review

References (44)

1. NCI-sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 47: 201-14.
2. Horning SJ, Rosenberg SA. The natural history of initially untreated non-Hodgkin's lymphomas. N Engl J Med, 1984; 311: 1471-5.
3. Pinkus G. Needle biopsy in malignant lymphoma. J Clin Oncol, 1996; 14: 2415-6.
4. Bastion Y, Berger F, Bryon P et al. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 2 (Suppl 2): 123-9.
5. Parker D, Alison DL, Barnard DL et al. Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level. Hematol Oncol, 1994; 12: 15-27.
6. Soubeynan P, Eghbali H, Bonichon F et al. Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. Eur J Cancer 1992; 27: 1606-13.
7. 2microglobulin in low-grade lymphoma. Ann Intern Med 1991; 114: 855-60.
8. Hermans J, Krol AD, van Groningen K et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995; 86: 1460-3.
9. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
10. The International Non-Hodgkin's Lymphoma Classification Project: Application of the International Lymphoma Study Group (ILSG) classification of non-Hodgkin's lymphoma (NHL): clinical characteristics and outcome of 1400 patients from 8 countries (Abstr). Ann Oncol 1996; 7: 2.
11. Press O, Horning S, Vose J. Evaluation and Management of the 'New' lymphoma entities: Mantle Cell lymphoma, MALT lymphoma, Monocytoid B cell lymphoma, and Anaplastic Large cell lymphoma. Education Program American Society of Hematology, 1996: 36-44.
12. Isaacson PG. The MALT lymphoma concept updated. Ann Oncol 1995; 6: 355-62.
13. Aisenberg AC. Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2656-75.
14. Hockenberry D, Nunez G, Milliman C et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334.
15. Merino R, Liyun D, Veis DJ et al. Development regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 1994; 13: 683-91.
16. Limpens J, Stad R, Vox C et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85: 2528-36.
17. Liu Y, Hernandez AM, Shabita D et al. Bcl-2 translocation frequency rises with age in humans. Ann NY Acad Sci, 1994; 91: 8910-14.
18. Schuler M, Huber C, Peschel C. Cytokines in the pathophysiology and treatment of chronic B-cell malignancies. Ann Hematol 1995; 71: 57-63.
19. Hanada M, Krajewski S, Tanaka S et al. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Canc Res 1993; 53: 4978-86.
20. Gribben JG, Neuberg D, Barber M et al. Detection of residual lymphoma cells by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-57.
21. Pendlebury S, El Awadi M, Ashley S et al. Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol 1995; 36: 167-71.
22. Kelsey SM, Newland AC, Vaughan Hudson G, Jeliffe AM. A British national lymphoma investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkin's lymphoma. Med Oncol, 1994; 11: 19-25.
23. Jelic S, From O, Jovanovic V et al. Watch and wait policy for patients with non-Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery (Abstr). Ann Oncol 1996; 7 (Suppl.): 55.
24. Soubeyran P, Eghbali H, Trojani M et al. Wait and see policy in stage I follicular lymphoma (abstract). Ann Oncol 1996; 7 (Suppl. 3): 144.
25. Young RC, Longo DL, Glatstein E et al. The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Sem Hematol, 1988; 25: 11.
26. Jones SE, Rosenberg SA, Kaplan HS et al. Non-Hodgkin's lymphomas: II. Single-agent chemotherapy. Cancer 1972; 30: 31-8.
27. Lister TA, Cullen MH, Beard ME et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of unfavourable histological type. B Med J, 1978; 1: 533-7.
28. Dana BW, Dahlberg S, Nathwani BN, Chase E. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol, 1993; 11: 644-51.
29. Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790-4.
30. Solal-Celigny P, Brice P, Brousse N, Caspard H. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14: 514-9.
31. Morton J, Taylor K, Bunce I et al. High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. B J Haem 1996; 95: 110-5.
32. McLaughlin P, Hagemeister FB, Romaguera JE et al. Fludarabine, mitoxantrone and dexamethasone: an effective new regiment for indolent lymphoma. J Clin Oncol, 1996; 14: 1262-8.
33. von Rohr A, Betticher DC, Racine C et al. Treatment with concurrent 2-chlorodeoxyadenosine (CDA) and interleukin-2 (IL-2) for low-grade B-cell malignancies avoids CDA-related lymphopenia: a pilot study. Ann Oncol 1996; 7 (Suppl. 3): 105.
34. Rohatiner AZ, Johnson PW, Price CG, Arnott SJ. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177-84.
35. Morel P, Laporte JP, Noel MP, Lopez M. Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia 1995; 9: 576-82.
36. Bastion Y, Brice P, Haioun C, Sonet A. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257-62.
37. Solal-Celigny P, Lepage E, Brousse N et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma: Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 1993; 329: 1608-14.
38. van Besien KW, Khouri IF, Giralt SA, McCarthy P. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995; 13: 1096-102.
39. Vander Molen LA, Steis RG, Duffey PL et al. Low-versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J Natl Cancer Ins 1990; 82: 235-8.
40. De Laurenzi A, Iudicone P, Zoli V et al. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects. J Hematother 1995; 4: 113-20.
41. Raspadori D, Lauria F, Ventura MA et al. Low doses of rL2 after autologous bone marrow transplantation induce a 'prolonged' immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas. Ann Hematol 1995; 71: 175-9.
42. McLaughlin P, Grillo-Lopez AJ, Czuczman M, Levy R. Pivotal phase III clinical trial of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed low-grade or follicular lymphoma: a preliminary report (abstr.). Ann Oncol 1996; 7 (Suppl. 3): 57.
43. Czuczman MS, Grillo-Lopez AJ, Jonas C et al. IDEC-C2B8 and CHOP chemotherapy of low-grade lymphoma (abstr.). Blood, 1995; 86 (Suppl.): 55a.
44. Longo DL. Immunotherapy for non-Hodgkin's lymphoma. Curr Opin Oncol, 1996; 8: 353-9.